Fig. 2 Relative mRNA expression of JAG1, HES1, and HEY2 in normal adrenal glands (NA), adenomas (ACA) and carcinomas (ACC)
and disease free survival (B, n=45) in patients with ACC.
Interestingly, high JAG1 expression was significantly associated with a longer overall and disease free survival (Fig 5A and B) . At multivariate analysis including the ENSAT stage, JAG1 maintained its independent impact on overall survival (P=0.007, HR=0.64, 25%CI: 0.46-0.89).
BACKGROUND:
Adrenocortical tumors consist of frequent benign adenomas (ACA) and rare highly malignant carcinomas (ACC) with a still incompletely understood pathogenesis. Dysregulation of the Notch signalling pathway is implicated in several cancers with oncogenic or tumor suppressor functions. Up-regulation of JAG1, a ligand of Notch receptor and a target gene for Notch and β-catenin pathway (Fig 1) , has been reported to enhance cell proliferation in ACC (Ref 1) , but no specific data on Notch1 pathway activation or JAG1 protein expression are available.
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JAG1 protein expression was absent or very low (H-score ≤1) in 72% of NA and in 61% of ACAs, but significantly higher in the ACCs (H-score >1 in 73% of ACCs, P<0.005, Fig 4A) . In the ACC group (n=126 patients who underwent first surgery), JAG1 expression was higher in patients with early ENSAT tumor stages than in those with metastatic disease (Fig 4B) . No other significant correlations were observed between JAG1 levels and clinical or histopathological parameters.
CONCLUSION:
P533 RESULTS: mRNA expression: NOTCH1 levels were similar in NA and in tumors. JAG1 and HES1 were slightly higher in ACC than in ACA, but HEY2 was significantly higher in ACC (Fig 2) . • Notch1 signaling pathway activation might be involved in adrenocortical tumor progression and needs to be further investigated.
• High JAG1 expression is associated with a better clinical outcome in ACC and might represent a new favorable prognostic marker. 
